Biogen Idec to Present at JPMorgan 23rd Annual Healthcare Conference.CAMBRIDGE, Mass. -- Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec Inc. (NASDAQ/BIIB) announced today that its presentation at the JPMorgan 23rd Annual Healthcare Conference in San Francisco, CA will be webcast live via the internet, at 5:30 pm EST EST electroshock therapy. EST abbr. electroshock therapy (2:30 pm PST PST Paroxysmal supraventricular tachycardia, see there ) on January 11, 2005. To access the live webcast, please visit Biogen Idec's homepage, www.biogenidec.com. An archived version of the webcast will be available for 30 days following the presentation. About Biogen Idec Biogen Idec creates new standards of care Standards of care are medical or psychological treatment guidelines, and can be general or specific. They specify appropriate treatment protocols based on scientific evidence, and collaboration between medical and/or psychological professionals involved in the treatment of a given in oncology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion